Guardant Paves a Commercial Path for Liquid Biopsy in Oncology

article image

Guardant's huge ambition to build a liquid biopsy business in cancer diagnostics is highlighted by its recent milestones in technically challenging indications like recurrence monitoring and earlier disease detection.

This much is certain: liquid biopsy technologies, not too long ago viewed as an aspirational achievement for select subsets of disease, are rapidly impacting clinical care in already diagnosed, advanced cancer patients. This excitement is reflected in investor interest: diagnostic test manufacturers, diagnostic testing services, and that new breed, precision medicine companies, overall outperformed the market last year, returning an average 41%.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: